3-year follow-up of peri-implantitis treatments
Long-term Stability of Peri-implantitis Treatments: a 3-year Clinical Evaluation
This follow-up will see if patients who had reconstructive surgery after initial non-surgical care keep their implants healthier over 3 years compared with those who had non-surgical therapy alone.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 34 (estimated) |
| Sex | All |
| Sponsor | Universitat Internacional de Catalunya Academic / other |
| Locations | 2 sites (Sant Cugat del Vallès, Bacelona and 1 other locations) |
| Trial ID | NCT07208643 on ClinicalTrials.gov |
What this trial studies
This prospective observational follow-up re-examines patients originally enrolled in the randomized PER-ECL-2019-05 trial to record clinical, radiographic, and patient-reported outcomes over a three-year period. The original trial randomized adults with advanced peri-implantitis to non-surgical therapy alone or to a non-surgical phase followed by reconstructive surgical therapy; this phase collects long-term maintenance and retreatment data without introducing new interventions. Study procedures include clinical periodontal/peri-implant exams, radiographs, and review of maintenance visits and any additional treatments or implant losses. The dataset will be used to compare long-term stability, recurrence rates, and factors linked to success or failure after the two initial treatment approaches.
Who should consider this trial
Good fit: Ideal candidates are adults who completed the original PER-ECL-2019-05 protocol (either non-surgical therapy alone or non-surgical plus reconstructive surgery) and are willing to provide informed consent for follow-up visits.
Not a fit: Patients who had their implant removed for reasons unrelated to peri-implantitis progression, those who developed systemic conditions that affect healing, those currently on antibiotics or antiresorptive therapy, and those who are pregnant or breastfeeding are unlikely to benefit from this follow-up.
Why it matters
Potential benefit: If successful, the follow-up could clarify which initial treatment approach provides better long-term implant stability, helping dentists choose treatments that reduce recurrence and implant loss.
How similar studies have performed: Prior long-term reports on peri-implantitis treatments are mixed—recurrence rates reported between about 20% and 50% over several years—so durable success of specific approaches remains uncertain.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Patiens previously enrolled in the randomized clinical trial PER-ECL-2019-05, which included 36 patients with advanced peri-implantitis. 2\. Completion of the original study protocol, including either reconstructive surgical therapy following a non-surgical phase or non-surgical therapy alone. 3.Signed informed consent for participation in the follow-up assessment. Exclusion Criteria: * 1.Did not complete the original clinical trial protocol (PER-ECL-2019-05) or withdrew before final evaluation. 2.Had the implant removed due to complications unrelated to peri-implantitis progression. 3.Have developed systemic diseases or conditions (e.g., uncontrolled diabetes, immunosuppression, malignancy) that may affect periodontal or peri-implant tissue healing or confound clinical outcomes. 4.Are currently undergoing antibiotic or antiresorptive therapy (e.g., bisphosphonates) that could interfere with bone metabolism. 5.Are pregnant or breastfeeding at the time of the follow-up visit. 6.Are unwilling or unable to attend the clinical follow-up appointment or provide informed consent.
Where this trial is running
Sant Cugat del Vallès, Bacelona and 1 other locations
- Hospital Universitari General de Catalunya — Sant Cugat del Vallès, Bacelona, Spain (Recruiting)
- Clinica Universitaria ́̀ d'Odontologia - UIC Barcelona at the Periodontology Department — Sant Cugat del Vallès, Barcelona, Spain (Recruiting)
Study contacts
- Principal investigator: CRISTINA VALLES CS VALLES, PhD — Universitat Internacional de Catalunya
- Study coordinator: cristina valles cv cristina valles DDS, MSc, PhD, PhD
- Email: cristinavallveg@uic.es
- Phone: 93 504 20 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.